Antihypertensive Treatment in NIDDM, with Special Reference to Abnormal Albuminuria

  • Paul G. McNally
  • Mark E. Cooper

Abstract

The deleterious effects of systemic blood pressure on glomerular structure were reported more than twenty years ago in a patient with NIDDM and unilateral renal artery stenosis, in which characteristic nodular diabetic glomerulosclerosis was present in the non-ischaemic kidney only [1]. Nevertheless, to date the impact of antihypertensive therapy on renal injury in NIDDM has received little attention even though the cumulative incidence of persistent proteinuria and microalbuminuria in NIDDM subjects is comparable in frequency to IDDM subjects of similar duration [2–5]. The clinical relevance of these figures is reflected by statistics which now show that over 50% of patients entering renal replacement programs have NIDDM [6–8]. Furthermore, in NIDDM the relationship between nephropathy and hypertension is more complex than in IDDM, since hypertension is not necessarily linked to the presence of renal disease, and often precedes the diagnosis of diabetes.

Keywords

NIDDM Patient Persistent Proteinuria Dihydropyridine Calcium Channel Blocker Conventional Therapy Group Microalbuminuric Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Berkman J, Rifkin H. Unilateral nodular diabetic glomerulosclerosis (Kimmelstiel-Wilson). Report of a case. Metabolism 1973; 22: 715–722.Google Scholar
  2. 2.
    Ballard DJ, Humphrey LL, Melton JI, Frohnert PP, Chu C, O’Fallon WM, Palumbo PJ. Epidemiology of persistent proteinuria in Type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes 1988; 37: 405–412.PubMedCrossRefGoogle Scholar
  3. 3.
    Kunzelman CL, Pettitt DJ, Bennett PH, Knowler WC. Incidence of nephropathy in Type 2 diabetes mellitus. Am J Epidemiol 1985; 122: 547–548.Google Scholar
  4. 4.
    Ritz E, Hasslacher C, Tschope W. Diabetic Nephropathy — are there differences between Type I and Type II. Miner Electrolyte Metab 1990; 16: 69–72.PubMedGoogle Scholar
  5. 5.
    Gall MA, Rossing P, Skott P, Damsbo P, Vaag A, Bech K, Dejgaard A, Lauritzen M, Lauritzen E, Hougaard P, Beck-Nelson H, Parving HH. Prevalence of micro-and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991; 34: 655–661.PubMedCrossRefGoogle Scholar
  6. 6.
    Grenfell A, Bewick M, Parsons V, Snowden S, Taube D, Watkins PJ. Non-insulin-dependent diabetes and renal replacement therapy. Diabetic Med 1988; 5: 172–176.PubMedCrossRefGoogle Scholar
  7. 7.
    US Renal Data System. 1989 Annual Data Report. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases; 1989.Google Scholar
  8. 8.
    Selby JV, Fitzsimmons SC, Newman JM, Katz PP, Sepe S, Showstack J. The natural history and epidemiology of diabetic nephropathy. JAMA 1990; 263: 1954–1960.PubMedCrossRefGoogle Scholar
  9. 9.
    Stornello M, Valvo EV, Puglia N, Scapellato L. Angiotensin converting enzyme inhibition with a low dose of enalapril in normotensive diabetics with persistent proteinuria. J Hypertens 1988; 6: suppl. 4: S464–S466.Google Scholar
  10. 10.
    Stornello M, Valvo EV, Scapellato L. Angiotensin converting enzyme inhibition in normotensive type II diabetics with persistent mild proteinuria. J Hypertens 1989; 7: suppl. 6: S314–S315.Google Scholar
  11. 11.
    Stornello M, Valvo EV, Vasques E, Leone S, Scapellato L. Systemic and renal effects of chronic angiotensin converting enzyme inhibition with Captopril in hypertensive diabetic patients. J Hypertens 1989; 7: suppl. 7: S65–S67.Google Scholar
  12. 12.
    Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 112: 707–708.PubMedCrossRefGoogle Scholar
  13. 13.
    Stornello M, Valvo EV, Scapellato L. Hemodynamic, renal, and humeral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor Captopril in hypertensive type II diabetic patients with nephropathy. J Cardiovasc Pharmacol 1989; 14: 851–855.PubMedCrossRefGoogle Scholar
  14. 14.
    Demarie BK, Bakris GL. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 113: 987–988.PubMedCrossRefGoogle Scholar
  15. 15.
    Stornello M, Valvo EV, Scapellato L. Comparative effects of enalapril, atenolol and chlorthalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria. Nephron 1991; 58: 52–57.PubMedCrossRefGoogle Scholar
  16. 16.
    Valvo EV, Bedogna V, Casagrande P, Antiga L, Zamboni M, Bommartini F, Oldrizzi L, Rugiu C, Maschio G. Captopril in patients with type II diabetes and renal insufficiency: systemic and renal hemodynamic alterations. Am J Med 1988; 85: 344–348.PubMedCrossRefGoogle Scholar
  17. 17.
    Slataper R, Vicknair N, Sadler R, Bakris GL. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 1993; 153: 973–980.PubMedCrossRefGoogle Scholar
  18. 18.
    Gambardella S, Frontoni S, Felici MG, Spallone V, Gargiulo P, Morano S, Menzinger G. Efficacy of antihypertensive treatment with indapamide in patients with non-insulin-dependent diabetes and persistent microalbuminuria. Am J Cardiol 1990; 65: 46H-50H.CrossRefGoogle Scholar
  19. 19.
    Gambardella S, Frontoni S, Lala A, Felici MG, Spallone V, Scoppola A, Jacoangeli F, Menzinger G. Regression of microalbuminuria in type II diabetic, hypertensive patients after long-term indapamide treatment. Am Heart J 1991; 122: 1232–1238.PubMedCrossRefGoogle Scholar
  20. 20.
    Lacourcière Y, Nadeau A, Poirier L, Tancrède G. Captopril or conventional therapy in hypertensive type II diabetics. Three year analysis. Hypertension 1993; 21: 786–794.PubMedCrossRefGoogle Scholar
  21. 21.
    Baba T, Tomiyama T, Murabayashi S, Takebe K. Renal effects of nicardipine, a calcium antagonist, in hypertensive Type 2 (non-insulin-dependent) diabetic patients with and without nephropathy. Eur J Clin Pharmacol 1990; 38: 425–429.PubMedCrossRefGoogle Scholar
  22. 22.
    Melbourne Diabetic Nephropathy Study Group. Comparison between Perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 1991; 302: 210–216.CrossRefGoogle Scholar
  23. 23.
    Romero R, Salinas I, Lucas A, Abad E, Reverter JL, Johnston S, Sanmarti A. Renal function changes in microalbuminuric normotensive type II diabetic patients treated with angiotensin-converting enzyme inhibitors. Diabetes Care 1993; 16: 597–600.PubMedCrossRefGoogle Scholar
  24. 24.
    Cooper ME, Doyle AE. The management of diabetic proteinuria. Which antihypertensive agent? Drugs & Aging 1992; 2: 301–309.CrossRefGoogle Scholar
  25. 25.
    Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577–581.PubMedCrossRefGoogle Scholar
  26. 26.
    Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U et al. Microalbuminuria predicts mortality in non-insulin dependent diabetics. Diabetic Med 1984; 1: 17–19.PubMedCrossRefGoogle Scholar
  27. 27.
    Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984; 310: 356–360.PubMedCrossRefGoogle Scholar
  28. 28.
    Garber A, Vinik A, Crespin S. Detection and management of lipid disorders in diabetic patients. Diabetes Care 1992; 15: 1068–1074.PubMedGoogle Scholar
  29. 29.
    Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and Captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868–873.PubMedCrossRefGoogle Scholar
  30. 30.
    Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298: 1152–1157.PubMedCrossRefGoogle Scholar
  31. 31.
    Stein P, Black H. Drug treatment of hypertension in patients with diabetes mellitus. Diabetes Care 1991; 14: 425–448.PubMedCrossRefGoogle Scholar
  32. 32.
    Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of Captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991; 303: 81–87.PubMedCrossRefGoogle Scholar
  33. 33.
    Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 1993; 118: 129–138.PubMedCrossRefGoogle Scholar
  34. 34.
    Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990; 38: 384–390.PubMedCrossRefGoogle Scholar
  35. 35.
    Rossing P, Hommel E, Smidt UM, Parving HH. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 1993; 42: 715–719.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Paul G. McNally
  • Mark E. Cooper

There are no affiliations available

Personalised recommendations